Regulus Therapeutics Inc. (RGLS) News

Regulus Therapeutics Inc. (RGLS): $2.07

0.06 (+2.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RGLS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

Filter RGLS News Items

RGLS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RGLS News Highlights

  • For RGLS, its 30 day story count is now at 8.
  • Over the past 29 days, the trend for RGLS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • OPGN and HERA are the most mentioned tickers in articles about RGLS.

Latest RGLS News From Around the Web

Below are the latest news stories about Regulus Therapeutics Inc that investors may wish to consider to help them evaluate RGLS as an investment opportunity.

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the completion of enrollment in the Phase 2 HERA clinical study evaluating lademirsen (RG-012) for the treatment of adult patients with Alport Syndrome under the Company's Collaboration and License Agreement with Sanofi.

Yahoo | February 24, 2022

Regulus Therapeutics Inc. (NASDAQ: RGLS) Stock Dropped -6.08% Over A Month Are There Any Chances Of Growth?

During the last session, Regulus Therapeutics Inc. (NASDAQ:RGLS)s traded shares were 0.45 million, with the beta value of the company hitting 2.02. At the end of the trading day, the stocks price was $0.23, reflecting an intraday loss of -6.62% or -$0.02. The 52-week high for the RGLS share is $2.32, that puts it down Regulus Therapeutics Inc. (NASDAQ: RGLS) Stock Dropped -6.08% Over A Month Are There Any Chances Of Growth? Read More »

Marketing Sentinel | February 19, 2022

Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO , Feb. 10, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS ), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present at the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 3:00 p.m. ET . A live webcast of the presentation will be available under "Events and Presentations" through the … Full story available on Benzinga.com

Benzinga | February 10, 2022

5 Penny Stocks Insiders Are Buying: OpGen, Regulus Therapeutics And More

The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above market estimates of 5.5%. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. OpGen The Trade: OpGen, Inc. (NASDAQ: OPGN ) Chief Operating Officer Johannes Bacher acquired a total of 25,000 shares at an average price of $0.85. To acquire these shares, it cost $21.2...

Benzinga | January 27, 2022

Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Regulus (RGLS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | January 26, 2022

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Regulus (RGLS) and Kura Oncology (KURA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intuitive Surgical (ISRG – Research Report), Regulus (RGLS – Research Report) and Kura Oncology (KURA – Research Report). Intuitive Surgical (ISRG) In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Intuitive Surgical, with a price target of $360.00. The company's shares closed last Thursday at $292.73. According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of -17.7% and a 21.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Brian Anderson on TipRanks | January 21, 2022

Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company has completed a pre-investigational new drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to obtain input from the FDA on pre-clinical, clinical and regulatory matters pertaining to the Company's next generation compound RGLS842

Yahoo | January 20, 2022

Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ...

Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..

Yahoo | January 19, 2022

Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 10-13, 2022. An on-demand webcast presentation will be available on Monday, January 10, 2022 at 7:00 a.m. ET.

Yahoo | January 4, 2022

An In-Depth Look At Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Inc. (NASDAQ:RGLS) has a beta value of 2.01 and has seen 1.38 million shares traded in the last trading session. The company, currently valued at $32.57M, closed the last trade at $0.36 per share which meant it gained $0.02 on the day or 5.83% during that session. The RGLS stock price is -544.44% An In-Depth Look At Regulus Therapeutics Inc. (RGLS) Read More »

Marketing Sentinel | December 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5202 seconds.